|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
KR100477070B1
(ko)
|
1994-03-25 |
2006-04-21 |
이소테크니카 인코포레이티드 |
중수소화작용에의한의약품의효능강화법
|
|
US6969712B2
(en)
*
|
2000-11-15 |
2005-11-29 |
Banyu Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
|
DK1360202T3
(da)
|
2001-02-16 |
2008-09-22 |
Conjuchem Biotechnologies Inc |
Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
|
|
EP1369698A1
(en)
|
2002-06-07 |
2003-12-10 |
Bayer Ag |
Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5)
|
|
WO2005051890A1
(en)
|
2003-11-19 |
2005-06-09 |
Smithkline Beecham Corporation |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
|
|
US7829307B2
(en)
|
2003-11-21 |
2010-11-09 |
Nps Pharmaceuticals, Inc. |
Production of glucagon-like peptide 2
|
|
JP4859665B2
(ja)
|
2004-03-30 |
2012-01-25 |
武田薬品工業株式会社 |
アルコキシフェニルプロパン酸誘導体
|
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
EP1844023A1
(en)
|
2004-12-31 |
2007-10-17 |
Sk Chemicals Co., Ltd. |
Quinazoline derivatives for the treatment and prevention of diabetes and obesity
|
|
CN101106991A
(zh)
|
2005-01-28 |
2008-01-16 |
默克公司 |
抗糖尿病的双环化合物
|
|
JP2008528628A
(ja)
|
2005-01-31 |
2008-07-31 |
メルク エンド カムパニー インコーポレーテッド |
抗糖尿病性二環式化合物
|
|
DE602006020123D1
(de)
|
2005-05-04 |
2011-03-31 |
Zealand Pharma As |
Glucagon-like-peptide-2- (glp-2-) analoga
|
|
BRPI0611138A2
(pt)
|
2005-06-02 |
2010-08-17 |
Hoffmann La Roche |
compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de sst subtipo 5 e utilização dos compostos
|
|
US20080221088A1
(en)
|
2005-06-23 |
2008-09-11 |
Vijay Kumar Potluri |
3,4-Substituted Thiazoles as Ampk Activators
|
|
AU2006264649A1
(en)
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
GPCR agonists
|
|
AU2006321743A1
(en)
|
2005-10-24 |
2007-06-14 |
Centocor, Inc. |
GLP-2 mimetibodies, polypeptides, compositions, methods and uses
|
|
JP5075641B2
(ja)
|
2006-01-31 |
2012-11-21 |
武田薬品工業株式会社 |
遺伝子改変動物およびその用途
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
NZ571110A
(en)
|
2006-04-11 |
2011-03-31 |
Arena Pharm Inc |
Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual
|
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
|
AU2007254325B2
(en)
|
2006-05-15 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
FR2903695B1
(fr)
|
2006-07-13 |
2008-10-24 |
Merck Sante Soc Par Actions Si |
Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
KR100826108B1
(ko)
|
2006-08-04 |
2008-04-29 |
한국화학연구원 |
퓨란-2-카복실산 유도체 및 그의 제조 방법
|
|
EP2059517A1
(en)
|
2006-08-30 |
2009-05-20 |
Biovitrum AB (publ) |
Pyrimidine compounds for treating gpr119 related disorders
|
|
US7812121B2
(en)
|
2006-08-31 |
2010-10-12 |
Baker Audrey E |
GLP-2 mimetibodies, polypeptides, compositions, methods and uses
|
|
WO2008063768A2
(en)
|
2006-10-12 |
2008-05-29 |
Case Western Reserve University |
Compositions and methods for treating metabolic diseases
|
|
AU2007314405A1
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
AU2007319066B2
(en)
|
2006-11-08 |
2013-09-19 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (GLP-2) analogues
|
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
|
WO2008067222A1
(en)
|
2006-11-28 |
2008-06-05 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
JP5330260B2
(ja)
|
2006-12-06 |
2013-10-30 |
スミスクライン ビーチャム コーポレーション |
二環式化合物ならびに抗糖尿病薬としての使用
|
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
|
ES2627221T3
(es)
|
2006-12-28 |
2017-07-27 |
Rigel Pharmaceuticals, Inc. |
Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
|
|
CA2928178C
(en)
|
2007-01-19 |
2019-09-10 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
US20080186971A1
(en)
|
2007-02-02 |
2008-08-07 |
Tarari, Inc. |
Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
|
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
DE602008002733D1
(de)
|
2007-03-08 |
2010-11-04 |
Irm Llc |
Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
|
|
EP2152707B1
(en)
|
2007-05-04 |
2012-06-20 |
Bristol-Myers Squibb Company |
[6,5]-bicyclic gpr119 g protein-coupled receptor agonists
|
|
PE20090222A1
(es)
|
2007-05-04 |
2009-03-27 |
Bristol Myers Squibb Co |
Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
|
|
KR20080099174A
(ko)
|
2007-05-07 |
2008-11-12 |
주식회사 머젠스 |
비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
|
|
PL2170864T3
(pl)
|
2007-07-17 |
2012-02-29 |
Bristol Myers Squibb Co |
Agoniści receptora gpr119 sprężonego z białkiem g - pirydon
|
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
JP5427784B2
(ja)
|
2007-09-21 |
2014-02-26 |
サノフイ |
(カルボキシルアルキレン−フェニル)−フェニル−オキサルアミド、その製造方法、及び薬剤としてのその使用
|
|
MX2010002419A
(es)
|
2007-09-21 |
2010-03-30 |
Sanofi Aventis |
(ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
|
|
US8354273B2
(en)
|
2007-10-17 |
2013-01-15 |
Universidad De Cordoba |
Isoforms of human somatostatin receptor type 5
|
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
|
SI2206707T1
(sl)
|
2007-10-24 |
2014-11-28 |
Astellas Pharma Inc. |
Azolkarboksamidna spojina ali njena sol
|
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
|
TWI421070B
(zh)
|
2007-10-26 |
2014-01-01 |
Japan Tobacco Inc |
螺化合物及其醫藥用途
|
|
AU2008319418B2
(en)
|
2007-10-29 |
2013-08-15 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
EP2231666B1
(en)
|
2007-12-12 |
2015-07-29 |
Rigel Pharmaceuticals, Inc. |
Carboxamide, sulfonamide and amine compounds for metabolic disorders
|
|
US20110172244A1
(en)
|
2008-02-22 |
2011-07-14 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
WO2009105717A1
(en)
|
2008-02-22 |
2009-08-27 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
KR20100120689A
(ko)
|
2008-02-22 |
2010-11-16 |
아이알엠 엘엘씨 |
Gpr119 활성의 조절제로서의 화합물 및 조성물
|
|
WO2009106561A1
(en)
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Pyrazine compounds for treating gpr119 related disorders
|
|
WO2009106565A1
(en)
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Agonists of gpr119
|
|
WO2009117421A2
(en)
|
2008-03-17 |
2009-09-24 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
PL2280704T3
(pl)
|
2008-03-31 |
2015-10-30 |
Cymabay Therapeutics Inc |
Związki oksymetylenoarylowe i ich zastosowania
|
|
BRPI0911118A2
(pt)
|
2008-04-07 |
2015-10-06 |
Irm Llc |
composto e compisições como moduladores de atividade de gpr119
|
|
KR101630466B1
(ko)
|
2008-04-11 |
2016-06-14 |
메르크 파텐트 게엠베하 |
Amp-활성화 단백질 키나아제(ampk) 활성화제로서의 티에노피리돈 유도체
|
|
WO2009132136A1
(en)
|
2008-04-23 |
2009-10-29 |
Rigel Pharmaceuticals, Inc. |
Carboxamide compounds for the treatment of metabolic disorders
|
|
KR101648593B1
(ko)
|
2008-05-05 |
2016-08-16 |
메르크 파텐트 게엠베하 |
Amp-활성화된 단백질 키나아제 (ampk) 활성화제로서의 티에노피리돈 유도체
|
|
CA2724426A1
(en)
|
2008-05-19 |
2009-11-26 |
Schering Corporation |
Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
|
|
US8188098B2
(en)
|
2008-05-19 |
2012-05-29 |
Hoffmann-La Roche Inc. |
GPR119 receptor agonists
|
|
NZ590503A
(en)
|
2008-06-16 |
2012-08-31 |
Merck Patent Gmbh |
Quinoxalinedione derivatives
|
|
BRPI0914891A2
(pt)
|
2008-06-20 |
2015-11-24 |
Metabolex Inc |
agonistas de aril gpr119 e usos dos mesmos
|
|
US8215922B2
(en)
|
2008-06-24 |
2012-07-10 |
Aurora Sfc Systems, Inc. |
Compressible fluid pumping system for dynamically compensating compressible fluids over large pressure ranges
|
|
ES2429129T3
(es)
|
2008-07-11 |
2013-11-13 |
Irm Llc |
4-Fenoximetilpiperidinas como moduladores de la actividad de GPR119
|
|
TW201006821A
(en)
|
2008-07-16 |
2010-02-16 |
Bristol Myers Squibb Co |
Pyridone and pyridazone analogues as GPR119 modulators
|
|
WO2010014739A2
(en)
|
2008-07-29 |
2010-02-04 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
US8796249B2
(en)
|
2008-07-30 |
2014-08-05 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
|
WO2010013849A1
(ja)
|
2008-08-01 |
2010-02-04 |
日本ケミファ株式会社 |
Gpr119作動薬
|
|
WO2010016846A1
(en)
|
2008-08-08 |
2010-02-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
US20110171164A1
(en)
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
|
CN102361857B
(zh)
|
2008-09-26 |
2015-09-16 |
默沙东公司 |
可用作抗糖尿病剂的环状苯并咪唑衍生物
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
US8410284B2
(en)
*
|
2008-10-22 |
2013-04-02 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
JP2012507530A
(ja)
|
2008-10-29 |
2012-03-29 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病剤である新規な環状ベンズイミダゾール誘導体
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
JP5514831B2
(ja)
|
2008-11-17 |
2014-06-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病の治療のための置換二環式アミン
|
|
HUE039171T2
(hu)
|
2008-11-19 |
2018-12-28 |
Intercept Pharmaceuticals Inc |
TGR5 modulátorok és azok alkalmazási eljárása
|
|
AU2009316484B2
(en)
|
2008-11-19 |
2015-04-16 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
|
JP5485292B2
(ja)
|
2008-12-12 |
2014-05-07 |
ポクセル・エスアーエス |
Ampk活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
|
|
WO2010085522A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Pentafluorosulpholane-containing antidiabetic compounds
|
|
EP2389226B1
(en)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
|
WO2010085528A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
|
JP2012517479A
(ja)
|
2009-02-12 |
2012-08-02 |
エグゼリクシス, インコーポレイテッド |
糖尿病および肥満の処置においてtgr5アゴニストとして使用するためのトリアゾールおよびイミダゾール誘導体
|
|
KR20120022801A
(ko)
|
2009-04-22 |
2012-03-12 |
아스텔라스세이야쿠 가부시키가이샤 |
카르복실산 화합물
|
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
|
EP2427448A1
(en)
|
2009-05-08 |
2012-03-14 |
Pfizer Inc. |
Gpr 119 modulators
|
|
US20120172351A1
(en)
|
2009-06-09 |
2012-07-05 |
Nobuyuki Negoro |
Novel fused cyclic compound and use thereof
|
|
AR077638A1
(es)
|
2009-07-15 |
2011-09-14 |
Lilly Co Eli |
Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
|
|
EP2474540A4
(en)
|
2009-08-31 |
2013-03-13 |
Nippon Chemiphar Co |
GPR119 AGONIST
|
|
GB0915892D0
(en)
|
2009-09-10 |
2009-10-14 |
Smithkline Beecham Corp |
Compounds
|
|
WO2011030139A1
(en)
|
2009-09-11 |
2011-03-17 |
Astrazeneca Ab |
4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
|
|
WO2011032320A1
(en)
|
2009-09-21 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Novel alkene oxindole derivatives
|
|
EP2483281B1
(en)
|
2009-10-01 |
2014-06-04 |
Cymabay Therapeutics, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
|
CA2774573A1
(en)
|
2009-10-09 |
2011-04-14 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
|
CA2779398A1
(en)
|
2009-10-30 |
2011-05-05 |
Mochida Phamaceutical Co., Ltd. |
Novel 3-hydroxy-5-arylisoxazole derivative
|
|
WO2011061679A1
(en)
|
2009-11-23 |
2011-05-26 |
Pfizer Inc. |
Imidazo-pyrazoles as gpr119 inhibitors
|
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
|
WO2011069298A1
(en)
|
2009-12-11 |
2011-06-16 |
F. Hoffmann-La Roche Ag |
Novel cyclopropane indolinone derivatives
|
|
JP2013513605A
(ja)
|
2009-12-11 |
2013-04-22 |
エグゼリクシス, インコーポレイテッド |
Tgr5アゴニスト
|
|
PH12012501456A1
(en)
|
2009-12-25 |
2012-10-29 |
Mochida Pharm Co Ltd |
Novel 3-hydroxy -5- arylisothiazole derivative
|
|
PT2519527E
(pt)
|
2009-12-29 |
2014-02-17 |
Poxel |
Tieno[2,3-b]piridinodiona como activadores de ampk e suas utilizações terapêuticas
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
JP2013522279A
(ja)
|
2010-03-18 |
2013-06-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
|
|
US8415367B2
(en)
|
2010-04-08 |
2013-04-09 |
Bristol-Myers Squibb Company |
Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
|
|
US8344137B2
(en)
|
2010-04-14 |
2013-01-01 |
Hoffman-La Roche Inc. |
3,3-dimethyl tetrahydroquinoline derivatives
|
|
US20130053407A1
(en)
|
2010-05-05 |
2013-02-28 |
Glaxosmithkline Llc |
Pyrrolo [3,2-d] pyrimidin-3-yl derivatives used as activators of ampk
|
|
CN102971311B
(zh)
|
2010-05-06 |
2015-07-08 |
百时美施贵宝公司 |
作为gpr119调节剂的二环杂芳基化合物
|
|
EP2566862B1
(en)
|
2010-05-06 |
2015-09-16 |
Bristol-Myers Squibb Company |
Benzofuranyl analogues as gpr119 modulators
|
|
JP5794297B2
(ja)
|
2010-05-07 |
2015-10-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gpr119アゴニストとしてのピリダジノン
|
|
AU2011256455A1
(en)
|
2010-05-17 |
2013-01-10 |
Array Biopharma Inc. |
Piperidinyl-substituted lactams as GPR119 modulators
|
|
JP2013529210A
(ja)
|
2010-05-18 |
2013-07-18 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Sstr5アンタゴニストとしてのスピロイソオキサゾリン化合物
|
|
TW201209054A
(en)
|
2010-05-28 |
2012-03-01 |
Prosidion Ltd |
Novel compounds
|
|
WO2011150067A1
(en)
|
2010-05-28 |
2011-12-01 |
Glaxosmithkline Llc |
Treatment of blood lipid abnormalities and other conditions
|
|
US20110313160A1
(en)
|
2010-06-04 |
2011-12-22 |
Metabolex, Inc. |
Preparation of 5-ethyl-2--pyrimidine
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
BR112012032248A2
(pt)
|
2010-06-23 |
2016-09-13 |
Metabolex Inc |
composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
|
US8592594B2
(en)
|
2010-07-02 |
2013-11-26 |
Hoffmann-La Roche Inc. |
Tetrahydro-quinoline derivatives
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
IN2013CN01340A
(cg-RX-API-DMAC7.html)
|
2010-07-23 |
2015-08-07 |
Connexios Life Sciences Pvt Ltd |
|
|
HUE052110T2
(hu)
|
2010-07-29 |
2021-04-28 |
Rigel Pharmaceuticals Inc |
AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
|
|
US8742110B2
(en)
|
2010-08-18 |
2014-06-03 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
|
WO2012025811A1
(en)
|
2010-08-23 |
2012-03-01 |
Lupin Limited |
Indolylpyrimidines as modulators of gpr119
|
|
US20120053180A1
(en)
|
2010-08-27 |
2012-03-01 |
Chemizon, A Division Of Optomagic Co., Ltd. |
Cyclohexane analogues as gpr119 agonists
|
|
JP5908478B2
(ja)
|
2010-08-30 |
2016-04-26 |
エヌピーエス ファーマシューティカルズ インコーポレイテッドNps Pharmaceuticals, Inc. |
h「Gly2」GLP−2の固相合成
|
|
KR101889993B1
(ko)
*
|
2010-09-10 |
2018-08-20 |
시오노기세야쿠 가부시키가이샤 |
Ampk 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체
|
|
CN103221046A
(zh)
|
2010-09-17 |
2013-07-24 |
阵列生物制药公司 |
作为gpr119调节剂的哌啶基取代的内酰胺
|
|
SG188547A1
(en)
|
2010-10-08 |
2013-04-30 |
Cadila Healthcare Ltd |
Novel gpr 119 agonists
|
|
JP2014001144A
(ja)
|
2010-10-08 |
2014-01-09 |
Nippon Chemiphar Co Ltd |
Gpr119作動薬
|
|
AU2011313191A1
(en)
|
2010-10-08 |
2013-05-02 |
Mochida Pharmaceutical Co., Ltd. |
Cyclic amide derivative
|
|
EP2646425B1
(en)
|
2010-12-01 |
2015-06-10 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
|
|
WO2012077655A1
(ja)
|
2010-12-07 |
2012-06-14 |
塩野義製薬株式会社 |
Gpr119アゴニスト活性を有するスピロ誘導体
|
|
WO2012082947A1
(en)
|
2010-12-16 |
2012-06-21 |
Irm Llc |
Compounds and compositions as tgr5 agonists
|
|
UY33805A
(es)
|
2010-12-17 |
2012-07-31 |
Boehringer Ingelheim Int |
?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
|
|
UY33871A
(es)
|
2011-01-21 |
2012-07-31 |
Boehringer Ingelheim Int |
Compuestos y formulaciones farmacéuticas basadas en derivados de benzo y heteroarilos condensados 2,3-dihidrofurán-2-il-piperidina y sus usos
|
|
US8809369B2
(en)
|
2011-01-26 |
2014-08-19 |
Hoffmann-La Roche Inc. |
Tetrahydroquinoline derivatives
|
|
CN102617548A
(zh)
|
2011-01-31 |
2012-08-01 |
北京赛林泰医药技术有限公司 |
作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
|
|
UY33913A
(es)
|
2011-02-17 |
2012-09-28 |
Takeda Pharmaceutical |
Método de producción de derivado de dihidrobenzofurano ópticamente activo
|
|
CA2826649C
(en)
*
|
2011-02-25 |
2016-07-26 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
JP2014094886A
(ja)
|
2011-02-28 |
2014-05-22 |
Nippon Chemiphar Co Ltd |
Gpr119作動薬
|
|
US20130345243A1
(en)
|
2011-03-07 |
2013-12-26 |
Glaxosmithkline Llc |
1h-pyrollo[3,2-d]pyrimidinedione derivatives
|
|
EP2683690A1
(en)
|
2011-03-07 |
2014-01-15 |
GlaxoSmithKline LLC |
Quinolinone derivatives
|
|
JP5977814B2
(ja)
|
2011-04-08 |
2016-08-24 |
アムジエン・インコーポレーテツド |
増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法
|
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
AR085990A1
(es)
|
2011-04-27 |
2013-11-13 |
Mochida Pharm Co Ltd |
Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen
|
|
US9062028B2
(en)
|
2011-04-28 |
2015-06-23 |
Bristol-Myers Squibb Company |
Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
|
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2013054338A1
(en)
|
2011-07-06 |
2013-04-18 |
Cadila Healthcare Limited |
2-thio-imidazole derivatives as tgr5 modulators
|
|
MX2014000452A
(es)
|
2011-07-15 |
2014-03-21 |
Shionogi & Co |
Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk).
|
|
AR087451A1
(es)
|
2011-08-17 |
2014-03-26 |
Lilly Co Eli |
Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
|
|
ES2687651T3
(es)
|
2011-09-12 |
2018-10-26 |
Amunix Operating Inc. |
Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
|
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
|
WO2013066869A1
(en)
|
2011-11-03 |
2013-05-10 |
Array Biopharma Inc. |
Piperidinyl-substituted lactams as gpr119 modulators
|
|
CA2855009C
(en)
|
2011-11-15 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
|
JP2015506349A
(ja)
|
2011-12-21 |
2015-03-02 |
アルデリックス, インコーポレイテッド |
非全身性tgr5アゴニスト
|
|
EP2803664B1
(en)
|
2012-01-12 |
2018-11-21 |
Jiangsu Hengrui Medicine Co. Ltd. |
Tetrahydrobenzofurane derivatives as gpr40 agonists for the treatment of diabetes
|
|
WO2013122029A1
(ja)
|
2012-02-13 |
2013-08-22 |
武田薬品工業株式会社 |
芳香環化合物
|
|
EP2816023A4
(en)
|
2012-02-13 |
2015-09-09 |
Takeda Pharmaceutical |
AROMATIC RING CONNECTION
|
|
WO2013122821A1
(en)
|
2012-02-14 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
|
TW201341356A
(zh)
|
2012-02-28 |
2013-10-16 |
皮拉馬爾企業有限公司 |
作為gpr促效劑之苯基烷酸衍生物
|
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
US8889730B2
(en)
|
2012-04-10 |
2014-11-18 |
Pfizer Inc. |
Indole and indazole compounds that activate AMPK
|
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
EA028929B1
(ru)
|
2012-05-03 |
2018-01-31 |
Зилэнд Фарма А/С |
Аналоги глюкагоноподобного пептида-2 (glp-2)
|
|
EP2847196B1
(en)
|
2012-05-07 |
2017-10-25 |
Boehringer Ingelheim International GmbH |
New 2,3-dihydro-furo[2,3-c]pyridines, their use as modulators of the g-protein-coupled receptor gpr119 and pharmaceutical compositions comprising them
|
|
US9174965B2
(en)
|
2012-05-16 |
2015-11-03 |
Bristol-Myers Squibb Company |
Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
|
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
|
EP2679591A1
(en)
|
2012-06-29 |
2014-01-01 |
Poxel |
Thienopyridone derivatives useful as activators of AMPK
|
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2014031445A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel benzimidazole tetrahydropyran derivatives
|
|
ES2755087T3
(es)
|
2012-08-22 |
2020-04-21 |
Merck Sharp & Dohme |
Derivados de benzimidazol hexahidrofuro[3,2-b]furano útiles como activadores de proteína cinasa activada por AMP
|
|
EP2888005B1
(en)
|
2012-08-22 |
2019-04-03 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
|
|
WO2014031517A1
(en)
*
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydrofuran derivatives
|
|
EP2888006B1
(en)
|
2012-08-22 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives useful as ampk activators
|
|
US9540364B2
(en)
|
2012-08-22 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
Benzimidazole tetrahydrofuran derivatives
|
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
|
AR092924A1
(es)
|
2012-10-09 |
2015-05-06 |
Sanofi Sa |
Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
|
|
NZ707389A
(en)
|
2012-10-26 |
2018-08-31 |
Intercept Pharmaceuticals Inc |
Process for preparing bile acid derivatives
|
|
WO2014069426A1
(ja)
|
2012-10-31 |
2014-05-08 |
塩野義製薬株式会社 |
Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体
|
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
|
HK1210144A1
(en)
|
2012-11-28 |
2016-04-15 |
勃林格殷格翰国际有限公司 |
New indanyloxydihydrobenzofuranylacetic acids
|
|
WO2014085474A1
(en)
|
2012-11-28 |
2014-06-05 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
|
JP6283862B2
(ja)
|
2012-12-07 |
2018-02-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシジヒドロベンゾフラニル酢酸
|
|
WO2014100025A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
|
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
|
WO2014096440A2
(en)
|
2012-12-21 |
2014-06-26 |
Novozymes Biopharma Dk A/S |
Composition
|
|
JP6314335B2
(ja)
|
2013-02-06 |
2018-04-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新しいインダニルオキシジヒドロベンゾフラニル酢酸
|
|
EP2769974A1
(en)
|
2013-02-21 |
2014-08-27 |
Debiopharm S.A. |
Novel AMPK activator
|
|
JP2016516004A
(ja)
|
2013-02-22 |
2016-06-02 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗糖尿病二環式化合物
|
|
JP6278472B2
(ja)
|
2013-02-27 |
2018-02-14 |
塩野義製薬株式会社 |
Ampk活性化作用を有するインドールおよびアザインドール誘導体
|
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
|
WO2014170842A2
(en)
|
2013-04-17 |
2014-10-23 |
Piramal Enterprises Limited |
Substituted alkyl carboxylic acid derivatives as gpr agonists
|
|
WO2014175330A1
(ja)
|
2013-04-24 |
2014-10-30 |
塩野義製薬株式会社 |
Ampk活性化作用を有する5-オキシベンズイミダゾールおよび5-オキシアザベンズイミダゾール誘導体
|
|
CN104870429B
(zh)
|
2013-05-22 |
2017-05-03 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
|
CA2914924A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceuticals B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
|
EP3010903A1
(en)
|
2013-06-20 |
2016-04-27 |
Boehringer Ingelheim International GmbH |
Olefin substituted oxindoles having ampk activity
|
|
JP2016525074A
(ja)
|
2013-06-20 |
2016-08-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ampk活性を有するスピロ置換オキシインドール誘導体
|
|
WO2015000412A1
(zh)
|
2013-07-02 |
2015-01-08 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
|
CN105377857B
(zh)
|
2013-07-17 |
2018-04-10 |
勃林格殷格翰国际有限公司 |
新颖氮杂苯并咪唑衍生物
|
|
WO2015010655A1
(zh)
|
2013-07-26 |
2015-01-29 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
|
LT3027642T
(lt)
|
2013-07-31 |
2020-10-12 |
Amgen Inc. |
Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
|
|
ES2672992T3
(es)
|
2013-08-09 |
2018-06-19 |
Takeda Pharmaceutical Company Limited |
Compuesto aromático
|
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
|
WO2015024526A1
(en)
|
2013-08-23 |
2015-02-26 |
Fujian Haixi Pharmaceuticals Co., Ltd |
Carboxylic acid compounds in treatment of diabetes mellitus
|
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
|
WO2015032328A1
(zh)
|
2013-09-03 |
2015-03-12 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
|
JP6533778B2
(ja)
|
2013-09-26 |
2019-06-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gpr40アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体
|
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
JP6474804B2
(ja)
|
2013-10-31 |
2019-02-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アザベンゾイミダゾール誘導体
|
|
WO2015062486A1
(en)
|
2013-10-31 |
2015-05-07 |
Sunshine Lake Pharma Co., Ltd. |
Biphenyl compounds and uses thereof
|
|
CN105722841A
(zh)
|
2013-11-14 |
2016-06-29 |
卡迪拉保健有限公司 |
新型杂环化合物
|
|
US10519115B2
(en)
|
2013-11-15 |
2019-12-31 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
HUE045926T2
(hu)
|
2013-11-26 |
2020-01-28 |
Chong Kun Dang Pharmaceutical Corp |
Amid-származékok GPR119 agonistákhoz
|
|
EP3074375B1
(en)
|
2013-11-28 |
2018-04-04 |
Boehringer Ingelheim International GmbH |
New indanyloxyphenylcyclopropanecarboxylic acids
|
|
WO2015084692A1
(en)
|
2013-12-04 |
2015-06-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
|
EP2886541A1
(en)
|
2013-12-19 |
2015-06-24 |
Sanofi |
Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases
|
|
US9617263B2
(en)
|
2014-01-10 |
2017-04-11 |
Eli Lilly And Company |
Phenyl-triazolo-pyridine compounds
|
|
US9809592B2
(en)
|
2014-01-10 |
2017-11-07 |
Eli Lilly And Company |
Isopropyl triazolo pyridine compounds
|
|
US10059667B2
(en)
|
2014-02-06 |
2018-08-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
|
AR099936A1
(es)
|
2014-04-04 |
2016-08-31 |
Sanofi Sa |
Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
|
|
RU2016143092A
(ru)
|
2014-04-04 |
2018-05-08 |
Санофи |
Замещенные соединения инданона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
|
|
AR099937A1
(es)
|
2014-04-04 |
2016-08-31 |
Sanofi Sa |
Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
|
|
WO2015160772A1
(en)
|
2014-04-15 |
2015-10-22 |
Janssen Pharmaceutica Nv |
Tetrahydro-benzoimidazolyl modulators of tgr5
|
|
US9884876B2
(en)
|
2014-05-09 |
2018-02-06 |
Kineta, Inc. |
Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
|
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
|
SI3626725T1
(sl)
|
2014-05-29 |
2023-04-28 |
Bar Pharmaceuticals S.R.L. |
Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
|
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
|
WO2016001224A1
(en)
|
2014-06-30 |
2016-01-07 |
Debiopharm International S.A. |
Novel activators of amp-activated protein kinases
|
|
WO2016000771A1
(en)
|
2014-07-02 |
2016-01-07 |
Arcelik Anonim Sirketi |
Built-in household appliance unpowered control and status indication device
|
|
WO2016022448A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
US10100042B2
(en)
|
2014-08-08 |
2018-10-16 |
Merck Sharp & Dohme Corp. |
[5,6]—fused bicyclic antidiabetic compounds
|
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
EP3180338B1
(en)
|
2014-08-11 |
2018-05-09 |
Boehringer Ingelheim International GmbH |
Azabenzimidazole derivatives as amp protein kinase agonistes
|
|
CN107108605A
(zh)
|
2014-08-27 |
2017-08-29 |
盐野义制药株式会社 |
具有ampk活化作用的氮杂吲哚衍生物
|
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
|
WO2016054208A1
(en)
|
2014-10-03 |
2016-04-07 |
Mayo Foundation For Medical Education And Research |
Targeting tgr5 to treat disease
|
|
TW201629033A
(zh)
|
2014-10-08 |
2016-08-16 |
健生藥品公司 |
作為治療第二型糖尿病之gpr40促效劑的經取代苯并噻吩基衍生物
|
|
WO2016068453A1
(en)
|
2014-10-27 |
2016-05-06 |
Dong-A St Co., Ltd. |
Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
|
|
CN107108521A
(zh)
|
2014-10-28 |
2017-08-29 |
盐野义制药株式会社 |
具有ampk活化作用的杂环衍生物
|
|
WO2016066818A1
(en)
|
2014-10-31 |
2016-05-06 |
Gubra Aps |
Compositions and peptides having dual glp-1r and glp-2r agonist activity
|
|
BR112017009657A2
(pt)
|
2014-11-06 |
2018-01-23 |
Enanta Pharmaceuticals, Inc |
análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
|
|
WO2016086115A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
|
|
WO2016092413A1
(en)
|
2014-12-10 |
2016-06-16 |
Pfizer Inc. |
Indole and indazole compounds that activate ampk
|
|
US10307402B2
(en)
|
2015-01-16 |
2019-06-04 |
Boehringer Ingelheim International Gmbh |
Azabenzimidazole derivatives as agonists of the AMP-activated protein kinase
|
|
US10053471B2
(en)
|
2015-01-16 |
2018-08-21 |
Boehringer Ingelheim International Gmbh |
Azabenzimidazole derivatives
|
|
AU2016219266A1
(en)
|
2015-02-11 |
2017-08-10 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
|
RU2712099C2
(ru)
|
2015-03-31 |
2020-01-24 |
Энанта Фармасьютикалс, Инк. |
Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
|
|
TW201712012A
(zh)
|
2015-06-16 |
2017-04-01 |
美國禮來大藥廠 |
2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物
|
|
JP2017011049A
(ja)
*
|
2015-06-19 |
2017-01-12 |
株式会社日立製作所 |
絶縁回路基板及びそれを用いたパワー半導体装置
|
|
TW201700447A
(zh)
|
2015-06-19 |
2017-01-01 |
英特賽普醫藥品公司 |
Tgr5調控劑及其用法
|
|
WO2017002786A1
(ja)
|
2015-07-02 |
2017-01-05 |
サントリーホールディングス株式会社 |
Glp-2分泌促進用組成物
|
|
WO2017025368A1
(en)
|
2015-08-07 |
2017-02-16 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
EP3331896A4
(en)
|
2015-08-07 |
2019-08-14 |
Intercept Pharmaceuticals, Inc. |
PROCESS FOR THE PRODUCTION OF GALLENIC ACID AND DERIVATIVES THEREOF
|
|
WO2017027310A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
|
US9920040B2
(en)
|
2015-08-12 |
2018-03-20 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
|
EP3347358B1
(en)
|
2015-09-09 |
2019-11-27 |
Boehringer Ingelheim International GmbH |
[{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
|
|
KR20180052756A
(ko)
|
2015-09-24 |
2018-05-18 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 유도체 제조를 위한 방법 및 중간체
|
|
CN108348533A
(zh)
|
2015-11-06 |
2018-07-31 |
英特塞普特医药品公司 |
制备奥贝胆酸及其衍生物的方法
|
|
WO2017106112A1
(en)
|
2015-12-16 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
|
|
TWI773657B
(zh)
|
2015-12-18 |
2022-08-11 |
美商亞德利克斯公司 |
作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
|
|
US10323060B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
|
|
US10364267B2
(en)
|
2016-02-23 |
2019-07-30 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017146186A1
(ja)
|
2016-02-26 |
2017-08-31 |
塩野義製薬株式会社 |
Ampk活性化作用を有する5-フェニルアザインドール誘導体
|
|
JP2019510739A
(ja)
|
2016-02-29 |
2019-04-18 |
イーライ リリー アンド カンパニー |
Gfral受容体療法
|
|
EP3436003B1
(en)
|
2016-03-29 |
2023-08-23 |
Merck Sharp & Dohme LLC |
Antidiabetic bicyclic compounds
|
|
US10526345B2
(en)
|
2016-04-08 |
2020-01-07 |
Mankind Pharma Ltd. |
Compounds as GPR119 agonists
|
|
US10208030B2
(en)
|
2016-04-08 |
2019-02-19 |
Mankind Pharma Ltd. |
GPR119 agonist compounds
|
|
US10106553B2
(en)
|
2016-04-11 |
2018-10-23 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
|
|
CA3020698A1
(en)
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating or preventing hepatocellular carcinoma
|
|
US20190135834A1
(en)
|
2016-04-26 |
2019-05-09 |
Shionogi & Co., Ltd. |
5-substituted azabenzimidazole derivative having ???? activation action
|
|
EP3459949A4
(en)
|
2016-05-20 |
2020-04-08 |
Shionogi & Co., Ltd |
5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT
|
|
WO2017222713A1
(en)
|
2016-06-24 |
2017-12-28 |
Indiana University Research & Technology Corporation |
A gpr119-based signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner
|
|
US11236055B2
(en)
|
2016-07-01 |
2022-02-01 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
|
US10654834B2
(en)
|
2016-07-01 |
2020-05-19 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
|
WO2018009778A1
(en)
|
2016-07-07 |
2018-01-11 |
Baylor College Of Medicine |
Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
|
|
WO2018026890A1
(en)
|
2016-08-03 |
2018-02-08 |
Cymabay Therapeutics |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
|
EP3500558B1
(en)
|
2016-08-19 |
2022-11-02 |
Rigel Pharmaceuticals, Inc. |
Benzimidazole direct ampk activators
|
|
CN109963567A
(zh)
|
2016-09-30 |
2019-07-02 |
英特塞普特医药品公司 |
胆汁酸衍生物的结晶形式
|
|
WO2018071493A1
(en)
|
2016-10-12 |
2018-04-19 |
Janssen Biotech, Inc. |
Methods for screening for modulators of gdf15-like biological activity
|
|
CN110088089B
(zh)
|
2016-10-25 |
2023-08-29 |
勃林格殷格翰国际有限公司 |
苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
|
|
WO2018081047A1
(en)
|
2016-10-25 |
2018-05-03 |
Janssen Pharmaceutica Nv |
Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
|
|
EP3544958B1
(en)
|
2016-11-28 |
2021-03-24 |
Boehringer Ingelheim International GmbH |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
|
AU2017373901B2
(en)
|
2016-12-09 |
2021-06-03 |
Zealand Pharma A/S |
GLP-1/GLP-2 dual agonists
|
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
WO2018138026A1
(en)
|
2017-01-26 |
2018-08-02 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
US10919859B2
(en)
|
2017-01-26 |
2021-02-16 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
CN110198928B
(zh)
|
2017-01-26 |
2023-08-29 |
勃林格殷格翰国际有限公司 |
苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
|
|
JP7049349B2
(ja)
|
2017-01-26 |
2022-04-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
|
JP7050792B2
(ja)
|
2017-01-26 |
2022-04-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
|
JP7049353B2
(ja)
|
2017-02-08 |
2022-04-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
|
|
AR110988A1
(es)
|
2017-02-21 |
2019-05-22 |
Sanofi Sa |
Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
|
|
WO2018161077A1
(en)
|
2017-03-03 |
2018-09-07 |
The Regents Of The University Of California |
Methods of treating conditions associated with leaky gut barrier
|
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
|
US11186565B2
(en)
|
2017-03-31 |
2021-11-30 |
Takeda Pharmaceutical Company Limited |
Aromatic compound
|
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
|
IT201700039562A1
(it)
|
2017-04-10 |
2018-10-10 |
Univ Pisa |
Derivati isoindolinici quali attivatori di ampk
|
|
IT201700039329A1
(it)
|
2017-04-10 |
2018-10-10 |
Univ Pisa |
Derivati benzofuranici quali attivatori di ampk
|
|
CN107162921B
(zh)
|
2017-05-27 |
2019-12-13 |
中国药科大学 |
一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
|
|
WO2018222701A1
(en)
|
2017-05-30 |
2018-12-06 |
Intercept Pharmaceuticals, Inc. |
Treatment of renal diseases with a bile acid derivative
|
|
WO2018226724A1
(en)
|
2017-06-05 |
2018-12-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
|
IL271245B2
(en)
|
2017-06-16 |
2023-10-01 |
Zealand Pharma As |
Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
|
|
IL271343B2
(en)
|
2017-06-23 |
2023-12-01 |
Intercept Pharmaceuticals Inc |
Methods and intermediates for the preparation of bile acid derivatives
|
|
AU2018321841A1
(en)
|
2017-08-22 |
2020-02-20 |
Shire-Nps Pharmaceuticals, Inc. |
GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
|
|
WO2019086559A1
(fr)
|
2017-10-31 |
2019-05-09 |
Adocia |
Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
CN111629745A
(zh)
|
2017-11-06 |
2020-09-04 |
夏尔-Nps医药品有限公司 |
用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies)
|
|
US11225471B2
(en)
|
2017-11-16 |
2022-01-18 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
DK3737470T5
(da)
|
2018-01-08 |
2024-05-27 |
Celon Pharma Sa |
3-phenyl-4-hexynsyrederivater som gpr40-agonister
|
|
EP3968976A1
(en)
|
2019-05-15 |
2022-03-23 |
Société des Produits Nestlé S.A. |
Phenanthrene ampk activator compounds, compositions, methods and uses thereof
|
|
MX2022014505A
(es)
*
|
2020-05-19 |
2022-12-13 |
Kallyope Inc |
Activadores de la ampk.
|
|
CA3183575A1
(en)
|
2020-06-26 |
2021-12-30 |
Iyassu Sebhat |
Ampk activators
|
|
WO2023097190A1
(en)
|
2021-11-23 |
2023-06-01 |
Kallyope, Inc. |
Ampk activators
|
|
TW202340185A
(zh)
|
2021-11-23 |
2023-10-16 |
美商克力歐普股份有限公司 |
Ampk活化劑
|
|
UY40034A
(es)
|
2021-11-23 |
2023-07-31 |
Kallyope Inc |
Activadores de la ampk
|